Salix Pharmaceuticals (NASDAQ:SLXP) is kicking off 2014 with a bigger sales team carrying big expectations following the company’s $2.8 billion acquisition of Santarus – expectations that pushed the ...
Released During Liver Health Awareness Month and Based Primarily on HCP-Market Research, Salix Pharmaceuticals' Liver Health Annual Trends Report Finds More than One-Third of Gastroenterologists ...
Valeant Pharmaceuticals International Inc.'s proposed acquisition of Salix Pharmaceuticals Ltd. and another recent deal position the company to expand in two new high-growth therapeutic areas, Valeant ...
Valeant’s plans to sell its Salix subsidiary to Japan’s Takeda are in disarray after negotiations fell apart at a late stage, according to reports. Citing unnamed sources, the Wall Street Journal says ...
After four years working to turn around Bausch Health's Salix Pharmaceuticals, President Mark McKenna is leaving. McKenna will this week become the CEO of a new precision medicine drug developer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results